VideaHealth Revenue, Valuation & Funding (2024)

VideaHealth reported annual recurring revenue of approximately $1.4 million as of the May 2022 interview, reflecting the early stage of its SaaS rollout following FDA clearance. Hillen declined to state a precise current revenue figure but confirmed that the implied math Nathan Latka derived, roughly $120,000 or more in monthly recurring revenue based on several hundred installed practices at $400 per practice per month, was "around it."

VideaHealth's primary customers are dental service organizations. Hillen said the company had signed contracts with dozens of DSOs as of May 2022, with those organizations collectively representing more than 3,000 office locations. The installed base at the time of the interview was described as "three digits," meaning several hundred practices, with the remaining contracted locations in active rollout expected to be completed within 12 to 14 months.

Pricing runs from $400 to $800 per practice per month depending on the software tier selected. Contracts are structured as annual minimums, with Hillen describing a standard minimum term of one year. The company was also developing partnerships to reach independent, non-DSO practices that Hillen described as "mom and pop" shops, though details of that channel were not yet public at the time of the interview.

VideaHealth operates a B2B SaaS model, selling annual software subscriptions to dental service organizations at $400 to $800 per practice per month. The company targets enterprise-level DSO customers rather than individual dentists, allowing it to sign one contract and roll out across hundreds of locations. Hillen described the SaaS motion as the company's strategic focus, contrasting it with the earlier pilot and insurance adjudication revenue that he characterized as closer to a services business.

The company also has a secondary revenue line serving insurance companies, automating the adjudication of dental claims. That business does not require FDA clearance and generated revenue during the period when the core diagnostic product was still in the regulatory process. Hillen did not break out the revenue contribution of the insurance line separately.

Profitability was not discussed in the interview. Gross margin, churn, net revenue retention, CAC, LTV, and burn rate were not disclosed. The company's FDA-cleared cavity detection algorithm was validated in a clinical study showing a 43 percent reduction in missed cavities and a 15 percent reduction in over-diagnosis errors, figures Hillen cited as central to the company's clinical and commercial positioning.

VideaHealth had 30 full-time employees as of the May 2022 interview. Hillen said the company had recently hired a director of talent and was targeting a headcount of 60 to 70 people by the end of 2022. He described the team as roughly equally split between engineering and product on one side and commercial functions on the other, with Series A capital allocated to hiring across both groups.